Skip to content
10-Q

Quarterly Report

BioLife Solutions, Inc. BLFS

0001628280-26-032148

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 48.86M sh
Shares Diluted Q1 2026 · Mar 31, 2026 49.25M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 48.37M sh
Capex Q1 2026 · Mar 31, 2026 $167K
Capex Q1 2026 · Mar 31, 2025 $175K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$491K
Operating Cash Flow Q1 2026 · Mar 31, 2025 $1.73M
Short Term Debt Q1 2026 · Mar 31, 2026 $2.5M
Short Term Debt Q1 2026 · Dec 31, 2025 $5M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $22.82M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $33.04M
Stockholders Equity Q1 2026 · Mar 31, 2026 $372.23M
Stockholders Equity Q1 2026 · Dec 31, 2025 $371.89M
Stockholders Equity Q1 2026 · Mar 31, 2025 $352.62M
Stockholders Equity Q1 2026 · Dec 31, 2024 $348.91M
Current Liabilities Q1 2026 · Mar 31, 2026 $18.25M
Current Liabilities Q1 2026 · Dec 31, 2025 $22.98M
Total Liabilities Q1 2026 · Mar 31, 2026 $28.68M
Total Liabilities Q1 2026 · Dec 31, 2025 $34M
Current Assets Q1 2026 · Mar 31, 2026 $133.22M
Current Assets Q1 2026 · Dec 31, 2025 $136.56M
Total Assets Q1 2026 · Mar 31, 2026 $400.91M
Total Assets Q1 2026 · Dec 31, 2025 $405.88M
Eps Diluted Q1 2026 · Mar 31, 2026 $0.02
Eps Diluted restated Q1 2026 · Mar 31, 2025 $0.00
Eps Basic Q1 2026 · Mar 31, 2026 $0.02
Eps Basic Q1 2026 · Mar 31, 2025 −$0.01
Sga Expense Q1 2026 · Mar 31, 2026 $12.21M
Sga Expense restated Q1 2026 · Mar 31, 2025 $11.35M
Rd Expense Q1 2026 · Mar 31, 2026 $2.65M
Rd Expense restated Q1 2026 · Mar 31, 2025 $1.44M
Net Income Q1 2026 · Mar 31, 2026 $1.19M
Net Income Q1 2026 · Mar 31, 2025 −$448K
Operating Income Q1 2026 · Mar 31, 2026 $27K
Operating Income restated Q1 2026 · Mar 31, 2025 −$499K
Gross Profit Q1 2026 · Mar 31, 2026 $17.5M
Gross Profit Q1 2026 · Mar 31, 2025 $14.8M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $10M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $7.25M